Y-mAbs Therapeutics Inc.

“We’re at an exciting juncture in medicine where the perceived scientific boundaries in treatment across therapeutic areas continue to dissolve.” These words from Jeffrey Jones , chief medical office

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Apollo Licenses Ex-China Rights T

Essential Pharma is best known as a generics player but the acquisition of fellow UK biotech Renaissance Pharma and its mid-stage immunotherapy for a rare type of childhood cancer shows the firm's

Eiger BioPharmaceuticals, Inc. ’s peginterferon lambda, Gilead Sciences, Inc. ’s magrolimab, Takeda Pharmaceutical Co. Ltd. ’s TAK-994 and Bavarian Nordic A/S ’s RSV vaccine are the latest entrants